Halaven (Eribulin Mesylate) Patent Expiration, LOE Window & CMS Spending
Halaven (Eribulin Mesylate) by Eisai: FDA Orange Book LOE 2027-07-08, 0 AB generics, $5.1M 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Eisai |
| FDA Application & Pathway | N201532 (NDA) |
| Exclusivity / Cliff Horizon | Immediate Cliff (2025-2027) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2027-07-08 |
| Orange Book Patents (*PED Extensions) | 2 patents (1 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $5.1M |
| 2024 Medicare Part D Spend | $281K |
| 2024 Medicaid Spend | $4.8M |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Eisai across sibling Meru public-data platforms.